Huya Bioscience International LLC, of San Diego, said the Japanese Ministry of Health, Labour and Welfare designated HBI-8000 an orphan drug in Japan for peripheral T-cell lymphoma. HBI-8000, a class I-selective oral histone deacetylase inhibitor, is completing a phase I open-label, dose-escalation trial in Japan, evaluating the drug's safety and pharmacokinetics in Japanese patients with non-Hodgkin lymphoma.